Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
2(25%)
Results Posted
233%(7 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
3
38%
Ph phase_3
2
25%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(3)
Terminated(3)

Detailed Status

Completed3
Terminated3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 32 (25.0%)

Trials by Status

completed338%
active_not_recruiting225%
terminated338%

Recent Activity

2 active trials
Showing 5 of 8
active_not_recruitingphase_1

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200
active_not_recruitingphase_1

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

NCT07217119
completedphase_2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

NCT03739710
terminatedphase_2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

NCT06790303
terminatedphase_3

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT04428333
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04126200Phase 1

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active Not Recruiting
NCT07217119Phase 1

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

Active Not Recruiting
NCT03739710Phase 2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed
NCT06790303Phase 2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Terminated
NCT04428333Phase 3

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated
NCT03693612Phase 1

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Completed
NCT04128696Phase 3

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated
NCT05553808Phase 2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8